Cargando…

HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast

Malignant adenomyoepithelioma (AME) of the breast is an exceptionally rare form of breast cancer, with a significant metastatic potential. Chemotherapy has been used in the management of advanced AME patients, however the majority of treatments are not effective. Recent studies report recurrent muta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bièche, Ivan, Coussy, Florence, El-Botty, Rania, Vacher, Sophie, Château-Joubert, Sophie, Dahmani, Ahmed, Montaudon, Elodie, Reyes, Cécile, Gentien, David, Reyal, Fabien, Ricci, Francesco, Nicolas, André, Marchio, Caterina, Vincent-Salomon, Anne, Laé, Marick, Marangoni, Elisabetta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424935/ https://www.ncbi.nlm.nih.gov/pubmed/34496925 http://dx.doi.org/10.1186/s13045-021-01158-3

Ejemplares similares

HORMAD1 overexpression predicts response to anthracycline–cyclophosphamide and survival in triple‐negative breast cancers
por: El‐Botty, Rania, et al.
Publicado: (2023)

Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers
por: Hatem, Rana, et al.
Publicado: (2016)

Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts
por: Coussy, Florence, et al.
Publicado: (2020)

Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers
por: Coussy, F., et al.
Publicado: (2020)

Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant
por: Jacquemetton, Julien, et al.
Publicado: (2021)

Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition
por: El Botty, Rania, et al.
Publicado: (2018)

Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers
por: ter Brugge, Petra, et al.
Publicado: (2023)

High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC
por: Montaudon, Elodie, et al.
Publicado: (2021)

PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance
por: Montaudon, Elodie, et al.
Publicado: (2020)

The Presence of an In Situ Component on Pre-Treatment Biopsy Is Not Associated with Response to Neoadjuvant Chemotherapy for Breast Cancer
por: Labrosse, Julie, et al.
Publicado: (2021)

Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas
por: Geyer, Felipe C., et al.
Publicado: (2018)

In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts
por: Passeri, Thibault, et al.
Publicado: (2022)

Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers
por: El-Botty, Rania, et al.
Publicado: (2023)

MED12 mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways
por: Laé, Marick, et al.
Publicado: (2016)

Interactive exploration of a global clinical network from a large breast cancer cohort
por: Sella, Nadir, et al.
Publicado: (2022)

PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer
por: Spasojevic, Caroline, et al.
Publicado: (2018)

Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore
por: Laas, Enora, et al.
Publicado: (2021)

Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer
por: Hamy, Anne-Sophie, et al.
Publicado: (2019)

Primary adenomyoepithelioma of tonsil
por: Ren, Juan, et al.
Publicado: (2010)

Primary adenomyoepithelioma of tonsil
por: Ren, Juan, et al.
Publicado: (2010)

Malignant adenomyoepithelioma of the breast
por: Moro, Kazuki, et al.
Publicado: (2020)

The Prognostic Value of Lymph Node Involvement after Neoadjuvant Chemotherapy Is Different among Breast Cancer Subtypes
por: Laot, Lucie, et al.
Publicado: (2021)

Biopathological Significance of PIWI–piRNA Pathway Deregulation in Invasive Breast Carcinomas
por: Meseure, Didier, et al.
Publicado: (2020)

Clinical value of R-spondins in triple-negative and metaplastic breast cancers
por: Coussy, F, et al.
Publicado: (2017)

Ultrasonographic Features of Benign Adenomyoepithelioma of the Breast
por: Lee, Ji Hye, et al.
Publicado: (2010)

Adenomyoepithelioma Located Over the Tibial Tuberosity
por: Kim, Kyung Taek, et al.
Publicado: (2013)

Malignant Adenomyoepithelioma of the Breast and Responsiveness to Eribulin
por: Lee, Suee, et al.
Publicado: (2015)

Breast adenomyoepithelioma, a case report
por: El-Helou, Etienne, et al.
Publicado: (2020)

Benign Adenomyoepithelioma of the Breast: Imaging Characteristics
Publicado: (2023)

A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways
por: Hamy, Anne-Sophie, et al.
Publicado: (2016)

No Impact of Smoking Status on Breast Cancer Tumor Infiltrating Lymphocytes, Response to Neoadjuvant Chemotherapy and Prognosis
por: Simon, Vanille, et al.
Publicado: (2020)

Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings
por: Bieche, Ivan, et al.
Publicado: (2014)

A case of adenomyoepithelioma with myoepithelial carcinoma of the breast
por: Ito, Ryota, et al.
Publicado: (2019)

Malignant adenomyoepithelioma of the breast: A case report
por: Lari, Eisa A., et al.
Publicado: (2020)

Adenomyoepithelioma of the Breast: A Report of 3 Cases
por: AlQurashi, Mariam, et al.
Publicado: (2022)

Benign adenomyoepithelioma of the breast: a case report
por: Belhaddad, El Habib, et al.
Publicado: (2022)

Malignant adenomyoepithelioma of the breast: A case report
por: Zhang, Zhihao, et al.
Publicado: (2021)

Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery
por: Gosset, Marie, et al.
Publicado: (2016)

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort
por: Hamy, Anne-Sophie, et al.
Publicado: (2018)

PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy
por: Grandal, Beatriz, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l3bitqgmnhq73m8ffibihoscq1